Novavax vaccine, to be made in India by SII, shows 90.4% efficacy in US trial

US-based biotech firm Novavax said that its COVID-19 vaccine NVX-CoV2373 has shown 90.4% overall efficacy and 93% efficacy against virus variants in Phase-3 trials. The vaccine showed 100% protection against moderate and severe disease based on the results of a study involving 29,960 participants across 119 US and Mexico sites. SII has agreed to manufacture the shot locally as Covovax.